This is the authors' abstract. We don't add key points for this paper.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death all over the world, and brings a heavy social economic burden especially in China. Several immuno-combination therapies have shown promising efficacy in the first-line treatment of unresectable HCC and are widely used in clinical practice. Nevertheless, which combination is the most affordable one is unknown. Our study assessed the cost-effectiveness of the immuno-combinations as first-line treatment for patients with unresectable HCC from the perspective of Chinese payers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: